News Seismic shakes up $121m for AI-designed immunology drugs Seismic Therapeutics has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.